DE60039240D1 - Neovaskulär gerichtete immunkonjugate - Google Patents

Neovaskulär gerichtete immunkonjugate

Info

Publication number
DE60039240D1
DE60039240D1 DE60039240T DE60039240T DE60039240D1 DE 60039240 D1 DE60039240 D1 DE 60039240D1 DE 60039240 T DE60039240 T DE 60039240T DE 60039240 T DE60039240 T DE 60039240T DE 60039240 D1 DE60039240 D1 DE 60039240D1
Authority
DE
Germany
Prior art keywords
immunoconjugates
alanine
factor vii
effector domain
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60039240T
Other languages
English (en)
Inventor
Alan Garen
Zhiwei Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Application granted granted Critical
Publication of DE60039240D1 publication Critical patent/DE60039240D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60039240T 1999-07-01 2000-06-14 Neovaskulär gerichtete immunkonjugate Expired - Lifetime DE60039240D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14216199P 1999-07-01 1999-07-01
PCT/US2000/016481 WO2001002439A1 (en) 1999-07-01 2000-06-14 Neovascular-targeted immunoconjugates

Publications (1)

Publication Number Publication Date
DE60039240D1 true DE60039240D1 (de) 2008-07-31

Family

ID=22498780

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60039240T Expired - Lifetime DE60039240D1 (de) 1999-07-01 2000-06-14 Neovaskulär gerichtete immunkonjugate

Country Status (11)

Country Link
EP (1) EP1198479B1 (de)
JP (2) JP2003504315A (de)
AT (1) ATE398633T1 (de)
AU (1) AU775621B2 (de)
CA (1) CA2377381C (de)
CY (1) CY1110394T1 (de)
DE (1) DE60039240D1 (de)
DK (1) DK1198479T3 (de)
ES (1) ES2307517T3 (de)
PT (1) PT1198479E (de)
WO (1) WO2001002439A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
EP1474451A2 (de) 2002-02-13 2004-11-10 Micromet AG Deimmunisierte (poly)peptidkonstrukte
US20060229239A9 (en) * 2002-03-08 2006-10-12 Mamoru Shoji Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
EP1485476A2 (de) * 2002-03-12 2004-12-15 Novo Nordisk A/S Dimerer tf-antagonist
AU2003242506A1 (en) * 2002-07-12 2004-02-02 Novo Nordisk A/S Tf antagonist
EP1523504A2 (de) * 2002-07-12 2005-04-20 Novo Nordisk A/S Gewebe faktorbindende immunokonjugate die faktor viia enthalten
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004239244C1 (en) 2003-05-06 2015-04-23 Bioverativ Therapeutics Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
AU2012203896B2 (en) * 2003-05-06 2014-09-25 Bioverativ Therapeutics Inc. Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
WO2005025623A2 (en) * 2003-07-28 2005-03-24 Emory University Ef-24-factor vii conjugates
CA2546580A1 (en) * 2003-11-18 2005-06-09 Iconic Therapeutics, Inc. Homogeneous preparations of chimeric proteins
JP2009203161A (ja) * 2006-06-05 2009-09-10 Mebiopharm Co Ltd リウマチ治療薬
WO2012006633A1 (en) * 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Chimeric clotting factors
EP3402537B1 (de) 2016-01-15 2021-01-06 Rigshospitalet Quantitative pet-bildgebung der gewebefaktorexpression mittels 18f-markiertem, durch an der aktiven stelle gehemmten faktor vii
EP3442554A4 (de) * 2016-04-14 2019-12-04 Iconic Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von erkrankungen im zusammenhang mit neovaskularisation
EP3541432A4 (de) 2016-11-17 2020-08-05 Minerva Imaging ApS 177-lu-markierter, durch aktive stelle inhibierter faktor vii
JP7155144B2 (ja) * 2017-03-14 2022-10-18 オハイオ・ステイト・イノベーション・ファウンデーション 組織因子標的化ＩｇＧ３免疫複合体に関連する方法及び組成物
WO2019067249A1 (en) * 2017-09-27 2019-04-04 Ohio State Innovation Foundation CAR-NK CELL THERAPY AND TISSUE FACTOR TARGETING T-CARD
WO2021030787A1 (en) * 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
DE69519929T2 (de) * 1994-07-11 2001-05-23 Univ Texas Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
US6132730A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
CA2377381A1 (en) 2001-01-11
JP2012255032A (ja) 2012-12-27
EP1198479B1 (de) 2008-06-18
EP1198479A4 (de) 2004-10-20
CY1110394T1 (el) 2015-04-29
AU5614900A (en) 2001-01-22
DK1198479T3 (da) 2008-10-13
ES2307517T3 (es) 2008-12-01
AU775621B2 (en) 2004-08-05
PT1198479E (pt) 2008-08-12
CA2377381C (en) 2013-06-11
ATE398633T1 (de) 2008-07-15
JP5745486B2 (ja) 2015-07-08
WO2001002439A1 (en) 2001-01-11
EP1198479A1 (de) 2002-04-24
JP2003504315A (ja) 2003-02-04

Similar Documents

Publication Publication Date Title
CY1110394T1 (el) Ανοσοσυζευγματα νεοαγγειακης στοχευσης
ES2224099T3 (es) Inmunotoxinas dirigidas contra antigenos de superficies relacionados con c-erbb-2 (her-2/neu).
AU665360B2 (en) Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
ATE246517T1 (de) Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
SA112330402B1 (ar) اتحادات جسم مضاد- عقار
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
WO2004032828A3 (en) Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
DE69530763D1 (de) Antikörper gegen e-selektin
DE69530109D1 (de) Zusammensetzung für behandlung von maligner tumore und ihre metastase
Muñoz et al. In vitro and in vivo effects of an anti-mouse endoglin (CD105)–immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours
KR20200135841A (ko) 고형 종양을 치료하기 위한 튜불린 교란제들을 포함하는 항체 약물 접합체들의 용도
Mansfield et al. Characterization of RFB4− Pseudomonas Exotoxin A Immunotoxins Targeted to CD22 on B-Cell Malignancies
NZ335353A (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases including AIDS or HIV
CA2366713A1 (en) Antibody and chemokine constructs and their use in the treatment of autoimmune diseases
US5690935A (en) Biotherapy of cancer by targeting TP-3/P80
Rathore et al. Generation of active immunotoxins containing recombinant restrictocin
WO2004007557A3 (en) Tf antagonist
WO1990011779A1 (en) Heteroconjugates
JPH09500869A (ja) トキシンの治療的使用に対する副作用および非感受性を防ぐ方法
Maiti et al. Tolerogenic conjugates of xenogeneic monoclonal antibodies with monomethoxypolyethylene glycol. I. Induction of long‐lasting tolerance to xenogeneic monoclonal antibodies
Ng et al. Cancer-homing toxins
WO2022268050A1 (zh) 一种药物组合及其用途
Engert et al. Experimental therapy in Hodgkin's disease
Morgan Jr et al. Preclinical and clinical evaluation of a monoclonal antibody to a human melanoma-associated antigen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition